The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Observational study of axilla treatment for breast cancer patients with 1 to 3 positive micrometastases or macrometastases in sentinel lymph nodes.
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Shigeru Imoto
No Relationships to Disclose
 
Takeshi Nagashima
No Relationships to Disclose
 
Tatsuya Onishi
No Relationships to Disclose
 
Tsutomu Takashima
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin Co., Ltd.; Novartis; Pfizer; Taiho Pharmaceutical
 
Masahiro Kitada
No Relationships to Disclose
 
Masaya Kawada
No Relationships to Disclose
 
Tetsu Hayashida
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Pfizer
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly; Taiho Pharmaceutical (Inst)
 
Yasuto Naoi
No Relationships to Disclose
 
Tomohiko Aihara
No Relationships to Disclose
 
Noriaki Wada
No Relationships to Disclose
 
Hidetaka Kawabata
No Relationships to Disclose
 
Masayuki Yoshida
No Relationships to Disclose
 
Uhi Toh
No Relationships to Disclose
 
Kimiyasu Yoneyama
No Relationships to Disclose
 
Akimitsu Yamada
No Relationships to Disclose
 
Hitoshi Tsuda
No Relationships to Disclose
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group ; Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa-Kirin; Lilly Japan; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Mari Saito-Oba
No Relationships to Disclose
 
Junichi Sakamoto
Consulting or Advisory Role - Olympus Medical Systems